Q-omics provides the consensus-scored RNU6-930P profile across patient tissues and cancer cell-line models. RNU6-930P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-930P is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, RNU6-930P RNA expression shows 16,694 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, LUAD, and DLBC as cancer lineages where RNU6-930P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-930P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-930P survival associations across molecular data types. RNU6-930P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-930P RNA expression–survival associations across cancer types. High RNU6-930P expression shows unfavorable associations in MESO, KIRP, CHOL and TGCT, but favorable associations in BLCA and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU6-930P RNA expression.
This table summarizes RNU6-930P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-930P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-930P shows higher tumor expression in LUAD, BLCA, KIRC, BRCA, COAD and PRAD. The LUAD box plot shows higher RNU6-930P RNA expression in tumor versus normal tissue (log2 FC = +0.581, t-test p < 0.001).
This table shows molecular features associated with RNU6-930P in patient tissues and cancer cell lines. In patient samples, RNU6-930P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
